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Abstract
Background—In 1998, the Centers for Disease Control and Prevention (CDC) published 
Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-
Related Chronic Disease, recommending HCV testing for populations most likely to be infected 
with HCV. However, the implementation of risk-based screening has not been widely adopted in 
health care settings, and 45% to 85% of infected U.S. adults remain unidentified.
Objectives—To develop a better understanding of why CDC’s 1998 recommendations have had 
limited success in identifying persons with HCV infection and provide information about how 
CDC’s 2012 Recommendations for the Identification of Chronic Hepatitis C Virus Infection 
Among Persons Born During 1945–1965 may be implemented more effectively.
Design—Qualitative data were collected and analyzed from a multidisciplinary team as part of 
the Birth Cohort Evaluation to Advance Screening and Testing for Hepatitis C project.
Respondents—Nineteen providers were asked open-ended questions to identify current 
perspectives, practices, facilitators, and barriers to HCV screening and testing. Providers were 
affiliated with Henry Ford Hospital, Mount Sinai Hospital, the University of Alabama, and the 
University of Texas Health Science Center.
Results—Respondents reported the complexity of the 1998 recommendations, and numerous 
indicated risk factors were major barriers to effective implementation. Other hindrances to 
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hepatitis C testing included physician discomfort in asking questions about socially undesirable 
behaviors and physician uncertainty about patient insurance coverage.
Conclusion—Implementation of the CDC’s 2012 recommendations could be more successful 
than the 1998 recommendations due to their relative simplicity; however, effective strategies need 
to be used for dissemination and implementation for full success.
Keywords
delivery of health care; guidelines; hepatitis; screening
INTRODUCTION
Approximately 3.2 million Americans are chronically infected with the hepatitis C virus 
(HCV; Davis, Alter, El-Serag, Poynard, & Jennings, 2010; Ly et al., 2012), and 45% to 85% 
of infected adults remain unidentified (Spradling et al., 2012). HCV-related morbidity and 
mortality are forecasted to grow exponentially over the next decade (Rein et al., 2011). In 
2007, more than 15,000 HCV-associated deaths were recorded. Chronic HCV infection is 
the leading cause of end-stage liver disease, and HCV-related medical costs are expected to 
exceed $6 billion annually by 2019 (Ly et al., 2012; National Center for HIV/AIDS, Viral 
Hepatitis, STD, & TB Prevention, 2010; Shehab, Orrego, Chunduri, & Lok, 2003). Studies 
have demonstrated the cost-effectiveness of testing to increase identification of persons 
living with HCV followed by treatment, if indicated (McEwan, Ward, Yuan, Kim, & 
L’Italien, 2013; McGarry et al., 2012; Rein et al., 2012). In 2012, the Centers for Disease 
Control and Prevention (CDC) recommended that all individuals born during 1945 to 1965 
(the birth cohort with the highest prevalence of HCV) receive a onetime test for HCV, 
assessment for alcohol use and intervention as indicated, and linkage to care and treatment 
as appropriate (Smith et al., 2012).
CDC’s 2012 recommendations supplement the 1998 recommendations, which indicated 
HCV testing of those with risks of exposure (Ghany, Strader, Thomas, & Seeff, 2009; 
Kaplan, Masur, & Holmes, 2002; National Center for Infectious Diseases, 1998; see Table 
1). CDC’s 1998 recommendations were subsequently supported and endorsed by The 
National Institutes of Health (2002) and the American Association for the Study of Liver 
Diseases (Strader, Wright, Thomas, & Seeff, 2004). To understand the potential challenges 
in implementing CDC’s new birth cohort recommendations, it is instructive to consider the 
degree to which CDC’s prior recommendations resulted in changes in HCV testing in 
clinical settings.
HCV infection typically presents without symptoms; therefore, risk assessments and HCV 
antibody testing in primary care are necessary to identify asymptomatic, chronically infected 
patients. Evidence suggests that the 1998 recommendations did not result in the widespread 
identification of HCV infection in the United States. In a sample of 208,752 primary care 
patients, only 26.2% of those with elevated liver enzymes, 33.7% of those who reported 
injection drug use, 33.3% of those who had received a blood transfusion before 1992, 61.8% 
of people with HIV, 24.1% of people with hemophilia, and 76.0% of those who had 
undergone hemodialysis had received an antibody test for HCV (Rein et al., 2012). 
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Furthermore, primary care providers do not appear to routinely conduct behavioral risk 
assessments that are needed to implement CDC’s 1998 recommendations (Almario, Vega, 
Trooskin, & Navarro, 2012; Clark, Yawn, Galliher, Temte, & Hickner, 2005; Navarro, St 
Louis, & Bell, 2003; Shehab et al., 2003). One study found that only 8% of patients who 
acknowledged having an HCV-related risk factor via an intake questionnaire in a primary 
care waiting room had been tested for HCV within 2 months of disclosing that risk (Almario 
et al., 2012). Although many primary care physicians (PCPs) test for HCV infection 
appropriately when patients volunteer risk information, few proactively elicit risk factor 
information (Navarro et al., 2003). A survey of active members of the American Academy of 
Family Physicians found that 37% of respondents reported not routinely asking patients 
about HCV risk factors (Clark et al., 2005).
Published studies suggest that the 1998 recommendations had attributes of other 
successfully implemented guidelines. For example, systematic reviews of the impact of 
clinical guidelines on quality of care found that successful change in care practice is based 
on strong evidence, addresses an area of uncertainty in clinician knowledge, is supported by 
an authoritative local or national professional body, is implemented during routine or chronic 
care, and is designed with extensive clinical input (Bazian Ltd., 2005; Grimshaw & Russell, 
1993). Gross (2001) found that engaging physicians and stakeholders, actively disseminating 
recommendations to physicians, and using local consensus conferences to build support for 
changes in practice were strategies that led to greater levels of implementation.
These studies also suggest barriers to implementation. Specifically, guidelines were more 
difficult to implement when physicians did not believe that benefits of implementation were 
significant, when physicians felt that following the guidelines was more difficult or time-
consuming than providing usual care, and when hospital administration viewed the 
guidelines as increasing costs (Bazian Ltd., 2005). Gross (2001) described approaches that 
were generally ineffective in changing physician behavior (e.g., dissemination of guidelines 
with limited to no follow-up). Finally, Burgers (2003) identified complex recommendations 
and the subsequent need for physician education and skill acquisition as principal barriers to 
the successful implementation of clinical recommendations.
CDC’s 1998 recommendations may have been viewed by providers as unlikely to result in 
patient benefit given the relatively low effectiveness of clinical therapy for HCV prior to 
2012 or uncomfortable to implement because they involved an explicit discussion of socially 
undesirable behavior (Modabbernia, Poustchi, & Malekzadeh, 2013) with patients. Practice 
administrators may have viewed the guidelines as likely to raise the cost of health care, with 
little benefit in terms of immediately offsetting costs or patient satisfaction. In addition, the 
CDC’s 1998 recommendations required physicians to remember multiple risks of exposure 
and clinical indicators and interview patients to elicit risk. Adoption of the recommendations 
may have been limited by these informational and skill acquisition barriers.
CDC’s 2012 birth cohort recommendations are intended to augment the 1998 
recommendations and should mitigate some of the barriers noted above because the focus is 
identification of a targeted group for HCV testing. However, addressing other systemic 
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problems, such as achieving institutional acceptance of the recommendations, may be as 
important as guideline simplification for expanding testing in primary care settings.
This article examines the perceptions of three groups of health professionals regarding 
implementation of CDC’s 1998 recommendations and the anticipated challenges to 
implementation of the birth cohort recommendations. Specifically, we seek to understand the 
extent to which PCPs, administrators, and hepatologists are familiar with CDC’s 1998 
recommendations, as well as how these health professionals view the benefits and impacts of 
the recommendations on patient well-being and clinical practice. The intended use of this 
study is to understand why the 1998 recommendations have had limited effectiveness in 
identifying a broader population of those infected with HCV and how CDC’s 2012 birth 
cohort testing recommendations can be effectively implemented in the future.
METHOD
Interviews
We collected data from four large primary care systems (Henry Ford Hospital, Detroit, 
Michigan; Mount Sinai Hospital, New York, New York; University of Alabama at 
Birmingham, Birmingham, Alabama; and University of Texas Health Science Center at 
Houston, Houston, Texas) as a component of the Birth Cohort Evaluation to Advance 
Screening and Testing for Hepatitis C. The study was approved by each primary care 
systems’ institutional review board. Informed consent was received from each participant. 
We conducted 19 interviews (six PCPs, eight hepatologists, and five administrators). 
Interviews were semistructured and lasted approximately 45 minutes.
We interviewed PCPs because the guidelines target providers to conduct hepatitis C testing; 
we interviewed administrators under the assumption that they could exert influence over the 
implementation of guidelines; and we interviewed hepatologists to understand better the 
barriers to linking patients diagnosed in primary care settings to specialist services.
Data Analysis
Interview data were analyzed to address research questions for PCPs, hepatologists, and 
administrators (see the appendix). Data coding and quality assurance were performed by a 
multidisciplinary team including research analysts, a project manager, the CDC project 
officer, a qualitative specialist, and a data research assistant. Intercoder reliability was 
83.0%. Data were organized and indexed by four of the authors using qualitative software 
(NVivo 9, QSR International). Employing grounded theory (Strauss, 1990), themes and 
subthemes were identified and validated by peer triangulation.
RESULTS
PCPs
All PCP respondents reported having been the provider of someone at risk for HCV. 
Providers identified the characteristics or behaviors used most commonly to identify patients 
for testing: history of injection drug use, multiple sexual partners, history of hepatitis B, 
positive test for HIV, and the presence of tattoos. Physicians placed the highest priority on 
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patients infected with HIV, patients with a history of injection drug use, and patients infected 
with hepatitis B.
A majority of the respondents reported conducting verbal assessments of the risk factors for 
HCV, without the aid of intake questionnaires or automated prompts from electronic record 
systems. One respondent reported that patients are presented with an intake questionnaire; 
however, the form does not include drug use history, and patients may choose not to fill out 
the form in its entirety. Another reported that the electronic record system prompts the 
physician to conduct behavioral assessments, such as drug use history.
Four of six respondents reported having prior knowledge of CDC’s 1998 recommendations 
for HCV testing. However, several inaccurately described the recommendations, such as 
recommended testing of those with multiple sex partners and those with tattoos. One 
respondent tested patients who received transfusion of blood or blood components before 
1990 instead of 1992. Another provider reported an awareness of the guidelines’ existence 
but was unfamiliar with their contents.
Overall, PCP respondents identified risk behavior assessment as the largest barrier to 
identifying patients for testing. They explained that PCPs do not routinely conduct 
behavioral assessments due to lack of time, lack of HCV knowledge among PCPs, and 
discomfort in asking patients about risk factors. Two PCPs cited discomfort of both the 
physician and the patient as a barrier to assessing patient risks, whereas two others reported 
confusion about clinical indications for testing.
All respondents reported ordering HCV testing on determining that a patient should be 
tested, before referring the patient to a specialist. Four reported conducting the process of 
referral to specialist care themselves, whereas two others used referral coordinators who 
assisted them with linking patients to specialist care. With the exception of one respondent, 
who stated that contacting a representative from the liver clinic treatment facility can 
sometimes be a problem, none of the others identified the referral procedure as a hindrance 
or a barrier to the testing of patients for HCV infection.
Respondents reported delays in scheduling appointments at the liver clinic, lack of insurance 
for uninsured or underinsured patients, patient resistance, and poor patient follow-through as 
the main barriers in linking patients to specialist care.
Hepatologists
Hepatologists reported having patients referred to them at various stages of the patients’ 
hepatitis C disease but only after they receive a positive HCV antibody test. Hepatologists 
listed delays in appointments at a liver clinic as the most common challenge of linking 
patients to specialist care. Three respondents reported wait times of 6 to 8 weeks to be seen 
by a hepatologist, once referred. Respondents reported receiving referrals from within their 
own hospital systems and from external sources; two stated that their hospital practices are 
not equipped to absorb large numbers of new patients.
Five of the eight hepatologists expressed concern about the lack of proper testing for 
hepatitis C by PCPs. They were concerned that physicians did not have adequate knowledge 
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about hepatitis C risk factors and felt uncomfortable discussing hepatitis C risk factors with 
patients. Hepatologists thought that physicians sometimes attempted to care for patients 
diagnosed with hepatitis C infection themselves instead of referring these patients to 
specialist care and that physicians did not test for hepatitis C because they prioritized testing 
for other health concerns such as cholesterol or cancer. One respondent stated that PCPs 
usually conduct hepatitis C testing only when they observe an abnormal alanine 
aminotransferase level.
Although hepatologists acknowledged that patients often face financial barriers to treatment, 
three described alternate methods for patients to obtain treatment. Two hepatologists 
reported that when their hospitals receive patients who lack insurance they are steered into 
clinical trials to receive treatment. Two hepatologists reported that patients without insurance 
can use drug companies’ charitable access or compassionate treatment programs to receive 
care. Thus, hepatologists did not necessarily view lack of insurance as a barrier to clinical 
treatment.
Administrators
Five administrators reported varying levels of involvement with hepatitis C testing. Three 
respondents stated their only involvement with HCV testing was through their normal 
primary care practice. One reported having no experience with HCV testing. Four 
respondents described supervising the operations and quality of care provided in their health 
care organization. One reported taking an active educational role in disseminating risk 
guidelines for hepatitis C testing.
Administrators reported having the influence to change hospital practices, including 
standardizing primary care practices and improving systemic adherence to practice 
guidelines. Three administrators specifically indicated that they have considerable influence 
over hospital residents, who are responsible for a large percentage of the primary care 
provided to patients.
Prospectively, the administrators interviewed suggested a number of different dissemination 
methods that could be used to promote adherence to CDC’s HCV testing recommendations, 
such as the use of educational media, grand rounds and other talks or academic conferences, 
yearly newsletters, and resident-training protocols. One respondent reported that although he 
was aware of CDC’s 1998 recommendations, the guidelines had not been distributed to 
physicians at his hospital. Two administrators reported that their hospital had not had any 
educational efforts related to hepatitis C guidelines in the past 5 years. Three reported having 
educational efforts related to hepatitis C during grand rounds and lunch conferences. One 
administrator reported that educational efforts at his hospital focused “more on treatment 
and less on testing.”
Four administrators reported that their clinic did not have a formal system for hepatitis C 
testing, and the decision to test for HCV was dependent on the individual PCP. Two 
administrators, however, expressed interest in the possibility of implementing a systematic 
testing procedure. One administrator reported that his clinic used the hepatitis C testing 
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guidelines issued by his municipality’s health department in place of the 1998 CDC 
recommendations.
Overall, administrators reported that the complexity of CDC’s 1998 recommendation was a 
hindrance to effective implementation. They commented that CDC’s 1998 recommendations 
include too many criteria and that PCPs lack the time to conduct behavioral assessments 
during appointments with patients. Two administrators specifically expressed enthusiasm for 
birth cohort testing; one commented, “Universal screening of an age cohort” would “make 
screening practices more formal and structured” and another concurred, “Screening by age 
group would be a much simpler process to follow.” One administrator reported, “Doctors 
don’t know what to follow” because of conflict between different sets of guidelines for the 
same clinical practice.
Administrators commented on the strengths and weaknesses of the referral system from 
PCPs to hepatologists. Two administrators expressed concern that referral systems did not 
allow PCPs to follow up with patients and ensure the referral appointment was completed. 
Administrators reported issues with insurance as a considerable barrier to effective testing 
and treatment. Two administrators reported that hepatologists may not be on an insurance 
provider list; in those cases, the clinic or the hospital needs to secure insurance 
preauthorization, which can be time-consuming and burdensome.
DISCUSSION
CDC’s 1998 recommendations have not identified a larger percentage of persons infected 
with HCV as anticipated. PCPs, hepatologists, and administrators provided institutional 
knowledge of HCV testing and the barriers that exist to identifying and caring for those 
infected with HCV. Research suggests four main reasons why the CDC’s 1998 
recommendation might not be fully implemented (Bazian Ltd., 2005; Burgers, 2003; Gross, 
2001; Solà et al., 2014). First, the large number of risk factors included in the 
recommendations requires physicians to acquire new knowledge, and their disinclination or 
lack of time to do so would inhibit testing. Second, providers are reluctant to elicit 
information that would call for testing because they are uncomfortable discussing socially 
stigmatizing behaviors with their patients, or lack time. Third, providers hesitate to test for 
HCV because they fear that patients’ insurers would not reimburse costs for testing or 
clinical treatment among newly diagnosed patients. Finally, some physicians believe that 
implementation of the guidelines will not benefit patients because patients will not access 
care and treatment or treatment might be ineffective.
The data revealed a number of misconceptions among PCPs about the contents of the 1998 
recommendations. Although the PCPs correctly identified two indications for testing—
injection drug use and HIV status—they inaccurately stated that individuals with multiple 
sex partners, hepatitis B infection, and a history of tattoos should also be tested for HCV. 
Other risk factors, such as a history of hemodialysis or hemophilia or a history of blood 
transfusions prior to 1992, were rarely mentioned. Respondents stated that the sheer number 
and complexity of the risk factors indicated in the 1998 recommendations served as a 
deterrent to physicians’ use of the guidelines.
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The current study also found evidence of physician discomfort with eliciting risk 
information from patients. Many providers denied that they were uncomfortable asking their 
patients about their past exposure history, even stigmatizing behavior, but rather stated that 
they lacked the time needed to collect patient histories during their primary care interactions, 
given the large number of recommendations that they were already expected to implement. 
Although PCPs reported little discomfort in asking patients about risk information, 
hepatologists almost universally perceived physician awkwardness and discomfort as the 
main reason that PCPs avoided taking patient history information.
Similarly, there was a difference in the attitudes displayed by PCPs, administrators, and 
hepatologists about the role of insurance coverage for HCV treatment. PCPs and 
administrators cited locating a hepatologist or a liver clinic that falls within the patients’ 
insurance provider list as a primary barrier to referral for care, and each group of 
respondents stated that this problem was greater for uninsured patients. Although 
hepatologists acknowledged that insurance coverage can sometimes act as a hindrance, only 
a few cited lack of insurance as a barrier to patient care and treatment, and several explicitly 
commented on the alternate options available to patients without insurance, such as 
enrollment in clinical trials or assistance from drug companies’ patient assistance programs. 
This suggests the need for clearer communication between PCPs, administrators, and 
hepatologists, to ensure that each group is fully informed about the options available for 
patients to receive care and treatment.
Finally, our data suggested reluctance among PCPs and hepatologists to treat patients for 
HCV with the expectation that more effective treatments would soon be available. Although 
skepticism of the efficacy of clinical treatment could have played some role in limiting HCV 
testing the reluctance applied only to treatment and not to testing.
Simpler recommendations with fewer indications requiring less knowledge and skill 
acquisition are likely to be more widely adopted as a routine element of clinical practice. In 
this regard, this evidence supports CDC’s birth cohort screening recommendation as a 
parsimonious method to target a population with a disproportionately high prevalence of 
unidentified HCV infection.
Strategies that public health advocates could pursue to encourage broader implementation of 
HCV testing include leveraging the authority of administrators within their organizations. 
This could greatly facilitate the dissemination of, and adherence to, birth cohort testing 
recommendations. The administrators reported having the authority to implement 
organization-wide policies on the use of clinical guidelines or having a significant influence 
over the clinical practices of medical residents in their organizations. However, they did not 
indicate a strong familiarity with the 1998 recommendations or that the 1998 
recommendations were particularly suited for implementation by PCPs (complexity of the 
guidelines, large number of risk factors, and conflict with other sets of guidelines). Given the 
enthusiasm that some of the administrators expressed for hepatitis C testing by birth cohort, 
it is possible that this group could be effective in advancing linkage to care by effectively 
disseminating and implementing the 2012 recommendations issued by the CDC.
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Last, additional medical personnel with the skills to evaluate and treat patients with HCV 
may be needed if the birth cohort strategy of case identification proves successful. 
Hepatologists revealed routine delays of 6 to 8 weeks between initial diagnosis and initial 
evaluation. Although hepatologists advocated for better testing by PCPs, several of them 
admitted that their current facilities were already operating at close to, if not beyond, 
maximum capacity.
It is worthwhile to note two major limitations. First, all interview subjects were aware, ahead 
of their scheduled interview, that they would be asked questions about hepatitis C and that a 
representative from the CDC would be observing the interview. The interview results may 
therefore overestimate respondents’ actual knowledge of and interest in HCV and CDC’s 
1998 recommendations. Second, the primary care systems that participated are large, 
integrated systems with practicing hepatologists; findings about the processes at these 
organizations may not be generalizable to all primary care settings.
CDC’s additional recommendations may be easier to implement than the 1998 
recommendations, as they do not require physicians to ask about a number of HCV risk 
factors and could make it feasible for physicians to identify persons at risk for HCV 
infection (based simply on birth year), even during short appointments. Overcoming the 
PCP’s limit on time is necessary for effective implementation, as other studies have reported 
(Katz et al., 2014). However, if the new recommendations are not disseminated and 
implemented effectively, they may not achieve their intended goal of identifying a greater 
proportion of the HCV-infected population. Administrators seem to have considerable 
authority over their institutions’ adoption of policies pertaining to clinical guidelines and 
thus should be more involved in the dissemination and implementation of the new 
recommendations. In addition, the shortage of specialist care needs to be addressed if 
patients are to receive timely and adequate treatment after receiving a diagnosis of HCV 
infection.
If CDC’s birth cohort screening recommendations are adopted widely by physicians, it is 
probable that there will be a considerable increase in the number of individuals identified as 
being infected with HCV; however, success is dependent on the availability of care to 
provide patients with treatment and medical support. There needs to be clearer 
communication between clinical and administrative staff to facilitate a comprehensive 
understanding of reimbursement options available to patients for HCV testing and treatment. 
In conclusion, the CDC birth cohort testing recommendations are likely to be more effective 
than the 1998 risk-based recommendations due to their relative simplicity, and efforts should 
be made to adopt and implement them broadly in primary care settings.
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APPENDIX. Research Questions Presented to Respondents for Each Health 
Professional Category
Primary Care Physicians (PCPs)
1. What risk factors do PCPs consider when testing patients, and to what extent do 
these risk factors align with those recommended in CDC’s 1998 guidelines?
2. From the perspective of PCPs, what are the main barriers to effective testing of 
patients at risk for HCV infection?
Hepatologists
1. What is the relationship between PCPs and hepatologists, and how does this 
relationship facilitate or hinder the testing of patients and the linkage of infected 
patients to clinical services?
2. Are hepatologists able to provide clinical care to the current HCV-infected 
patients referred to them in a timely and effective manner, and are they able to 
accommodate additional patients should the number referred to them increase?
Administrators
1. What emphasis do health system administrators place on the dissemination of 
CDC’s 1998 guidelines?
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2. What influence do administrators have to disseminate and encourage adherence 
to screening and testing guidelines for medical practice?
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TABLE 1
Persons Who Should be Tested routinely for HCV Infection based on Their risk for Infection
Persons who ever injected illegal drugsa
 Those who injected once or a few times many years ago and do not consider themselves as drug users
Persons with selected medical conditionsa
 Persons who received clotting factor concentrates produced before 1987
 Persons who were ever on chronic (long-term) hemodialysis
 Persons with persistently abnormal alanine aminotransferase levels
Prior recipients of transfusions or organ transplantsa
 Persons who were notified that they received blood from a donor who later tested positive for HCV infection
 Persons who received a transfusion of blood or blood components before July 1992
 Persons who received an organ transplant before July 1992
Persons who should be tested routinely for HCV infection based on a recognized exposurea
 Health care, emergency, medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV- positive blood
 Children born to HCV-positive women
Persons who are HIV infected should be tested routinely for evidence of chronic HCV infectionb
NOTE. HIV = human immunodeficiency virus.
aNational Center for Infectious Diseases (1998); Ghany, Strader, Thomas, and Seeff (2009).
b
Kaplan, Masur, and Holmes (2002).
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